FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Pfizer Prempro Recall

Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0

Pfizer Inc. · New York, NY

Risk level
Class III
Reported by FDA
Jul 10, 2013
Recall ID
D-630-2013
Check your lot numberHow we source this data

Summary

Pfizer recalled Prempro starting May 31, 2013. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-630-2013 on Jul 10, 2013. Reason: Failed Dissolution Specifications: Pfizer Inc. is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the dissolution specification for conjugated estrogens. Status: Terminated.

Why it was recalled

Failed Dissolution Specifications: Pfizer Inc. is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the dissolution specification for conjugated estrogens.

Product description

Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/2.5 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA, NDC 0046-0875-11

Lot numbers, UPCs & expiration codes

Lots: E67324 & E96152 Exp: 06/13

Where it was sold

Nationwide and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-630-2013
Classification
Class III
Status
Terminated
Recall initiated
May 31, 2013
FDA report date
Jul 10, 2013
Quantity
432,657 blister cards
Recall type
Voluntary: Firm initiated
Recalling firm
Pfizer Inc.

Original FDA data

Every field from FDA enforcement report D-630-2013, exactly as published.

Show all FDA fields
City
New York
State
NY
Status
Terminated
Country
United States
Event ID
65393
Address
235 East 42nd Street
Code information
Lots: E67324 & E96152 Exp: 06/13
Postal code
10017-5703
Report date
Jul 10, 2013
Product type
Drugs
Recall number
D-630-2013
Classification
Class III
Recalling firm
Pfizer Inc.
Product quantity
432,657 blister cards
Termination date
Apr 6, 2017
Reason for recall
Failed Dissolution Specifications: Pfizer Inc. is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product may not meet the dissolution specification for conjugated estrogens.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/2.5 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA, NDC 0046-0875-11
Distribution pattern
Nationwide and Puerto Rico
Recall initiation date
May 31, 2013
Initial firm notification
Letter
Center classification date
Jun 28, 2013

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-630-2013, published Jul 10, 2013. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls